Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

November 14, 2016November 14, 2016

Teenagers with Lymphoma at Almost 4-Fold Risk of Heart Disease in Adulthood, Study Says

News

Teenage and young adult cancer survivors, particularly those with lymphoma, appear to be at high risk of developing heart disease associated with cancer treatments, a large-scale study in the U.K. reports. The study, “Cardiac ... Read more

October 25, 2016October 26, 2016

Specific Elevated Blood Levels in Diffuse Large B-Cell Lymphoma May Predict Poor Patient Outcomes

News

Increased blood levels of beta-2 microglobulin in patients with diffuse large B-cell lymphoma (DLBCL) who were treated with the drug Rituxan (rituximab) can be a reliable predictor of poor prognosis, according to a new study. ... Read more

October 24, 2016

New Compound Shows Promise in Treatment of Lymphoma, Other Cancers

News

Researchers have identified a new compound called S63845 that blocks the growth of several different types of cancer, including lymphoma, according to a study published in the journal Nature. The ... Read more

October 7, 2016October 7, 2016

First B-Cell Lymphoma Patients Dosed in Phase 1 Study of Potential Therapy

News

Dosing of patients has begun in a Phase 1 clinical trial evaluating the safety and tolerability of Karus Therapeutics‘ lead anti-cancer candidate, KA2237, as a treatment for B-cell lymphoma, the company announced. The ... Read more

September 23, 2016

Blood Biomarkers Can Predict Survival of Patients with Diffuse Large B-Cell Lymphoma

News

New research shows that the number of platelets and the levels of a protein called albumin can serve as robust prognostic factors for patients with diffuse large B-cell lymphoma (DLBCL), ... Read more

September 20, 2016

Lymphoma Drug, Other Soligenix Therapies to Be Presented at Investment Conference

News

Soligenix President Christopher Schaber will present a company overview at the 2016 Aegis Growth Conference Sept. 20-22 in Las Vegas, Nevada. The company is developing SGX301 (synthetic hypericin), a molecule that can be activated by ... Read more

September 16, 2016September 16, 2016

Hodgkin’s Lymphoma Patients Respond Well in Study of Triple Combo Therapy with Adcetris

News

Patients with early stage, unfavorable risk classical Hodgkin’s lymphoma who are treated with Adcetris (brentuximab vedotin) and chemotherapy, followed by radiation therapy, are more likely to achieve complete responses than those ... Read more

September 12, 2016September 12, 2016

T-Cell and Chemo Combination Seen to Induce Remission in Advanced NHL Patients

News

Results from an early clinical study in advanced non-Hodgkin’s lymphoma (NHL) showed that 50 percent patients went into complete remission after receiving a combination of chemotherapy and JCAR014, a product based on Chimeric ... Read more

September 6, 2016September 6, 2016

Stem Cell Transplants to Treat Blood Cancers May Cause Immune Cells to Age as Much as 30 Years

News

Cancer treatments are known to have several side effects in patients, such as fatigue, nausea, and hair loss. Now, a study suggests that stem cell transplants may induce the premature aging ... Read more